Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 108.71M | 133.53M | 152.12M | 148.58M | 191.44M |
| Total Receivables | 30.77M | 31.78M | 38.60M | 31.08M | 27.96M |
| Inventory | 4.74M | 4.67M | 3.48M | 2.77M | 3.04M |
| Prepaid Expenses | 12.25M | 14.75M | 14.31M | 15.48M | 10.81M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 30.00K | 33.00K | 32.00K | 459.00K | 660.00K |
| Total Current Assets | 156.49M | 184.76M | 208.54M | 198.37M | 233.92M |
|
|
|||||
| Total Current Assets | 156.49M | 184.76M | 208.54M | 198.37M | 233.92M |
| Net Property, Plant & Equipment | 6.28M | 3.08M | 3.80M | 4.45M | 4.88M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 1.64M | 1.64M | 1.64M | 1.64M | 1.64M |
| Total Assets | 164.42M | 189.48M | 213.98M | 204.46M | 240.44M |
|
|
|||||
| Total Accounts Payable | 5.11M | 5.78M | 2.80M | 5.03M | 3.12M |
| Total Accrued Expenses | 60.65M | 50.11M | 49.81M | 54.85M | 61.39M |
| Short-term Debt | 24.43M | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 438.00K | 3.67M | 3.55M | 3.43M | 3.31M |
| Total Finance Division Other Current Liabilities | 1.64M | 1.94M | 1.47M | 2.04M | 1.65M |
| Total Other Current Liabilities | 1.64M | 1.94M | 1.47M | 2.04M | 1.65M |
| Total Current Liabilities | 92.26M | 61.49M | 57.62M | 65.34M | 69.48M |
|
|
|||||
| Total Current Liabilities | 92.26M | 61.49M | 57.62M | 65.34M | 69.48M |
| Long-Term Debt | 236.45M | 264.09M | 264.63M | 303.61M | 303.40M |
| Short-term Debt | 24.43M | -- | -- | -- | -- |
| Capital Leases | 6.71M | -- | 955.00K | 1.88M | 2.79M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 15.01M | 23.54M | 22.91M | 2.58M | 978.00K |
| Total Liabilities | 350.44M | 349.12M | 346.12M | 373.41M | 376.64M |
|
|
|||||
| Common Stock & APIC | 1.38B | 1.37B | 1.37B | 1.36B | 1.35B |
| Retained Earnings | -1.56B | -1.53B | -1.50B | -1.52B | -1.49B |
| Treasury Stock & Other | -356.00K | -222.00K | -605.00K | -518.00K | -161.00K |
| Total Common Equity | -186.02M | -159.65M | -132.14M | -168.96M | -136.21M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -186.02M | -159.65M | -132.14M | -168.96M | -136.21M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -186.02M | -159.65M | -132.14M | -168.96M | -136.21M |
|
|
|||||